Shuai Liu*†1, Lu Lu*†1, Feng Pan‡, Chunsheng Yang*†, Jing Liang§, Jinfeng Liu¶, Jian Wang#, Rong Shen**, Fu-Ze Xin††, Nan Zhang*†
Oncology Research, Vol.29, No.1, pp. 25-31, 2021, DOI:10.3727/096504022X16427607626672
Abstract Fruquintinib, also called HMPL-013, was first discovered by Hutchison Whampoa Pharmaceuticals Co. Ltd.,
Shanghai, China, and it is an oral vascular endothelial growth factor receptor (VEGFR) inhibitor. In clinical trials, fruquintinib has demonstrated a survival benefit in metastatic colorectal cancer (mCRC) patients. The purpose of this study was to retrospectively evaluate the efficacy and toxicity of fruquintinib in real-world patients.
We collected data from patients with mCRC treated with oral fruquintinib from 2018 to 2020 in six different
institutions. Patients with mCRC initially received 5 mg of oral fruquintinib daily for 3 weeks. Progression-free
survival (PFS) was evaluated using the… More >
Login
Register
